Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Hope S. Rugo, MD, director of Breast Oncology Clinical Trials Investigation at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting, Rugo says.
There was a marked improvement in pathologic complete response (pCR) rates with the addition of pembrolizumab (Keytruda) to standard neoadjuvant chemotherapy in the KEYNOTE-522 trial. This trial was uniquely powered for event-free survival in 1200 patients with TNBC.
This trial showed a significant improvement in pCR with the addition of pembrolizumab in the range of 64% to 65%. This was really encouraging, says Rugo, as these rates are higher than what’s been observed with the addition of platinum.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More